Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Destiny Pharma. (DEST)

Price 2.25p on 26-07-2024 at 16:30:01
Change -0.50p -18.18%
Buy 2.50p
Sell 2.00p
Buy / Sell DEST Shares
Last Trade: Buy 50,000.00 at 2.44p
Day's Volume: 1,196,097
Last Close: 2.25p
Open: 2.75p
ISIN: GB00BDHSP575
Day's Range 2.25p - 2.75p
52wk Range: 2.25p - 82.00p
Market Capitalisation: £2m
VWAP: 2.37391p
Shares in Issue: 96m

Recent Trades History Destiny Pharma. (DEST)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 50,000 2.44p Ordinary
15:29:32 - 26-Jul-24
Buy* 50,000 2.44p Ordinary
15:29:18 - 26-Jul-24
Buy* 20,491 2.44p Ordinary
15:27:21 - 26-Jul-24
Buy* 21,367 2.34p Ordinary
15:23:10 - 26-Jul-24
Buy* 60,000 2.34p Ordinary
15:19:47 - 26-Jul-24
Buy* 42,735 2.34p Ordinary
15:16:10 - 26-Jul-24
Sell* 350 2.11p Ordinary
15:12:43 - 26-Jul-24
Sell* 4,683 2.11p Ordinary
15:00:41 - 26-Jul-24
Sell* 20,000 2.11p Ordinary
14:51:59 - 26-Jul-24
Sell* 6,000 2.10p Ordinary
14:51:18 - 26-Jul-24

Share Price History for Destiny Pharma.

Time period:
to
Date Open High Low Close Volume

Share News for Destiny Pharma.

UK shareholder meetings calendar - next 7 days

24th Jul 2024 14:45

Read More

AIM WINNERS & LOSERS: Destiny Pharma falls on plans to go private

15th Jul 2024 10:38

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday. Read More

Destiny Pharma looks to go private to raise funds, avoid liquidation

15th Jul 2024 09:25

(Alliance News) - Destiny Pharma PLC on Monday proposed going private to pursue funding opportunities after failing to secure a licensing partner. Read More

IN BRIEF: Destiny Pharma presents "exciting" data for ringworm drug

18th Jun 2024 18:47

Destiny Pharma PLC - biotechnology company, focused on developing and commercialising medicines for life-threatening infections - Announces new data on one of its XF Drug Platform compounds, XF-70, which has demonstrated potency in an in vivo model of ringworm, a common fungal skin infection. Says ringworm affects up to one in four people worldwide. XF-70 is a member of a novel class of antimicrobial drugs. Says drug has been shown "to have a rapid bactericidal activity even within biofilms, and is structurally related to the company's leading drug, XF-73 which is being developed for the prevention of post-surgical staphylococcal infections." Read More

EARNINGS AND TRADING: Intuitive Investments NAV rises, talks up Hui10

12th Jun 2024 19:23

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

FTSE 100 Latest
Value8,285.71
Change99.36

Login to your account

Forgot Password?

Not Registered